2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints

BACKGROUND: Isavuconazole (ISC) was approved by the US FDA and is considered first-line therapy for the treatment of invasive aspergillosis (IA). Azole resistance in Aspergillus fumigatus (AFM) is a growing concern, mainly caused by mutations within CYP51 genes. The activity of ISC and other azoles...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby L, Hatch, Beth, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678784/
http://dx.doi.org/10.1093/ofid/ofad500.1736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678784/
http://dx.doi.org/10.1093/ofid/ofad500.1736

Ejemplares similares